Published by Global Banking and Finance Review
Posted on June 23, 2025
BERLIN (Reuters) -German medical technology firm Brainlab set the price range for its initial public offering at 80 to 100 euros per share on Monday, aiming for a market capitalisation of up to 2.1 billion euros ($2.41 billion), it said.
The Munich-based company plans to sell up to 5.2 million shares within a week, which would yield an issue volume of 520 million euros.
Brainlab's target market value of 1.67 billion to 2.09 billion euros is at the lower end of the previously stated upper valuation of 3 billion euros.
Its main products include software systems that are used as navigational tools by surgeons, for example during brain and hip surgery, and for spinal implants and fractures.
The offer period runs from Tuesday through July 1, with Brainlab set to debut on the Frankfurt Stock Exchange on July 3.
Between 160 million and 200 million euros from that issue volume will go to the company itself, with the remainder going to company founder Stefan Vilsmeier, his extended family and Munich-based financial investor EMH Partners.
"Strong interest in Brainlab from investors underscores that we are ideally positioned to drive and help shape the urgently needed digital transformation of healthcare," said Vilsmeier in a statement.
Depending on the final price, gross proceeds from a capital increase could bring in up to 200 million euros, which would be used to expand into other areas, such as orthopaedics, heart surgery and ear, nose and throat medicine.
($1 = 0.8697 euros)
(Reporting by Alexander Huebner; Writing by Miranda Murray; Editing by Tom Hogue and Louise Heavens)
Explore more articles in the Headlines category
